Tasly Pharmaceutical Group Co., Ltd
600535
Rang in aandelen
#4771
Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in... Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in Tianjin, China, is actively engaged in the biological medicine, health, and medical service industries within China. Its extensive product catalog encompasses a wide range of goods, including both traditional herbal and modern chemical medicines, alongside various health supplements. The firm also supplies key pharmaceutical ingredients (APIs), concentrated herbal granules, herbal extracts, and a diverse selection of tea products. Beyond its core pharmaceutical offerings, Tasly manufactures cosmetic lines featuring items such as moisturizing lotions, facial creams, eye creams, and cleansing foams. Additionally, its consumer goods division provides daily hygiene essentials like sanitary and carefree pads, in addition to specialized soaps made with honey-propolis and pollen. The company further distributes medical equipment, including different types of massage devices like tappers and cushions, as well as circulation-enhancing machines. Tasly's market presence extends globally, with significant exports directed to the United States, Russia, and numerous countries across Europe, Africa, and other parts of Asia.
Aandeelprijs
$2.05
Marktkapitalisatie
$3.07B
Verandering (1 dag)
-1.37%
Verandering (1 jaar)
-7.80%
Land
CN
Handel Tasly Pharmaceutical Group Co., Ltd (600535)
Categorie
Healthcare
Winst voor Tasly Pharmaceutical Group Co., Ltd (600535)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Tasly Pharmaceutical Group Co., Ltd bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Tasly Pharmaceutical Group Co., Ltd van 2001 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2025 | $192.27M | 31.32% |
| 2024 | $146.41M | -15.13% |
| 2023 | $172.51M | -809.84% |
| 2022 | $-24.30M | -105.67% |
| 2021 | $428.51M | 92.12% |
| 2020 | $223.04M | 16.70% |
| 2019 | $191.12M | -32.79% |
| 2018 | $284.34M | 6.54% |
| 2017 | $266.90M | 23.84% |
| 2016 | $215.52M | -22.05% |
| 2015 | $276.48M | -1.18% |
| 2014 | $279.80M | 19.89% |
| 2013 | $233.39M | 34.76% |
| 2012 | $173.19M | 38.94% |
| 2011 | $124.65M | 48.07% |
| 2010 | $84.18M | 44.00% |
| 2009 | $58.46M | 26.80% |
| 2008 | $46.10M | 49.47% |
| 2007 | $30.84M | -8.16% |
| 2006 | $33.58M | 16.86% |
| 2005 | $28.74M | 10.44% |
| 2004 | $26.02M | 22.03% |
| 2003 | $21.32M | 21.82% |
| 2002 | $17.50M | 12.42% |
| 2001 | $15.57M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
